EYPT
EyePoint Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.58
+0.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.8M | 31.4M | 43.3M | 46.0M | 41.4M |
| Cost of Revenue | 1.6M | 2.1M | 3.7M | 4.6M | 8.3M |
| Gross Profit | 1.2M | 29.3M | 39.6M | 41.4M | 33.1M |
| Operating Expenses | |||||
| R&D Expense | 262.7M | 221.0M | 132.9M | 64.7M | 49.6M |
| SG&A Expense | 55.4M | 51.7M | 52.5M | 51.8M | 60.3M |
| General & Admin Expense | 55.4M | 51.6M | 52.4M | 40.1M | 34.8M |
| Selling & Marketing Expense | 54.0K | 90.0K | 131.0K | 11.7M | 25.5M |
| Other Expenses | — | — | — | — | 22.7M |
| Total Operating Expenses | 318.1M | 272.7M | 185.4M | 116.5M | 132.7M |
| Cost and Expenses | 319.8M | 274.8M | 189.1M | 121.1M | 141.0M |
| Operating Income (EBIT) | (317.0M) | (243.4M) | (145.9M) | (75.1M) | (99.6M) |
| Non-Operating | |||||
| Interest Income | 10.5M | 11.8M | 15.1M | 6.9M | 2.1M |
| Interest Expense | — | — | 14.0K | 1.2M | 3.2M |
| Net Interest Income | 10.5M | 11.8M | 15.1M | 5.7M | (1.1M) |
| Other Non-Op Income/Expense | 10.5M | 11.8M | 15.1M | 4.4M | (2.6M) |
| Non-Operating Income (excl Interest) | (19.3M) | (11.8M) | (15.1M) | (5.6M) | (572.0K) |
| EBT (Pre-Tax Income) | (306.5M) | (231.7M) | (130.8M) | (70.7M) | (102.3M) |
| Income Tax Expense | (136.0K) | 279.0K | 90.0K | 83.0K | — |
| Bottom Line | |||||
| Net Income | (306.6M) | (232.0M) | (130.9M) | (70.8M) | (102.3M) |
| Earnings from Cont. Ops | (306.4M) | (232.0M) | (130.9M) | (70.8M) | (102.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (306.6M) | (232.0M) | (130.9M) | (70.8M) | (102.3M) |
| Per Share | |||||
| Basic EPS | ($3.74) | ($3.17) | ($2.32) | ($1.82) | ($2.74) |
| Diluted EPS | ($3.74) | ($3.17) | ($2.32) | ($1.82) | ($2.74) |
| Revenue Per Share | $0.03 | $0.43 | $0.77 | $1.18 | $1.11 |
| Shares | |||||
| Basic Shares Outstanding | 86.5M | 73.3M | 56.3M | 38.9M | 37.3M |
| Diluted Shares Outstanding | 86.5M | 73.3M | 56.3M | 38.9M | 37.3M |
| Profitability Metrics | |||||
| EBITDA | (294.4M) | (229.3M) | (129.2M) | (69.0M) | (96.6M) |
| D&A | 3.2M | 2.3M | 1.5M | 464.0K | 2.4M |
| EBIT | (297.6M) | (231.7M) | (130.8M) | (69.5M) | (99.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026